Clinical efficacy of SUN9216 (Modified tissue plasminogen activator) as compared to alteplase in patients with acute myocardial infarction: A multicenter randomized double-blind comparative study

Japanese Pharmacology and Therapeutics

Volumn 25, Issue 1, 1997, Pages 269-299

  Yui, Yoshiki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; LANOTEPLASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030885773     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fletcher AP et al : The maintenance of a sustained thrombolytic state in man II ; Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 38 : 1111-1119, 1959
2. Rentrop KP et al : Acute myocardial infarction ; Intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 2 : 354-363, 1979
3. Verstraete M : Intravenous administration of a thromtaolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. Eur Heart J 6 : 586-593, 1985
4. Collen D et al : Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 71 : 216-219, 1988
5. Larsen GR et al : Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 73 : 1842-1850, 1989
6. Gruppo Italiano per lo Studio della Streptochinasi nell' Infart Miocardico (GISSI) : Effectiveness of intravenous thrombolytic treatment in acute niyocardial infarction. Lancet i : 397-401, 1986
7. Chesebro JH et al : Thrombolysis in myocardial infarction (TIMI) trial, phase I ; A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76 : 142-154, 1987
8. Topol EJ et al : Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction ; Improved timing, trombolytic efficacy and ventricular function. JACC 10 : 1173-1177, 1987
9. Werf FV, Arnold AE : Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 297 : 1374-1379, 1988
10. National Heart Foundation of Australia Coronary Thrombolysis Group : Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet i : 203-207, 1988
11. White HD et al : Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. New Engl J Med 320 : 817-821, 1989
12. Verstraete M et al : Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 235 : 506-512, 1985
13. Seifried E et al : Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneim Forsch/Drug Res 38 : 418-422, 1988
14. Tanswell P et al : Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 46 : 155-162, 1989
15. Neuhaus KL et al : Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. JACC 14 : 1566-1569, 1989
16. Carney RJ et al : Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. JACC 20 : 17-23, 1992
17. The GUSTO Investigators : An international randomaized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 329 : 673-682, 1993
18. The GUSTO Angiographic Investigators : The effect of tissue plasminogen, activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. New Engl J Med 329 : 1615-1622, 1993
19. Gore JM et al : Stroke after thrombolysis ; Mortality and functional outcomes in the GUSTO-I trial. Circulation 92 : 2811-2818, 1995
20. ISIS-3 Collaborative group : ISIS-3 ; A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 339 : 753-770, 1992
21. Hsia J et al : A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. New Engl J Med 323 : 1433-1437, 1990
22. Bleich SD et al : Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66 : 1412-1417, 1990
23. Califf RM et al : Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction : Result of thrombolysis and angioplasty in myocardial infarction-phase 5 randomized trial. Circulation 83 : 1543-1556, 1991